The DOI matches its Crossref record.
Augmentation of Serotonin Reuptake Inhibitors in Refractory Obsessive-Compulsive Disorder Using Adjunctive Olanzapine: A Placebo-Controlled Trial
Abstract
BACKGROUND: The purpose of this study was to explore the efficacy of adding an atypical antipsychotic, olanzapine, to a serotonin reuptake inhibitor (SRI) in treatment-refractory obsessive-compulsive disorder (OCD). METHOD: Twenty-six patients aged between 18 and 65 (mean = 41.2, SD = 11.9) years meeting DSM-IV criteria for OCD, who had not responded to SRIs, were treated for 6 weeks in a double-blind, placebo-controlled augmentation study with either olanzapine (up to 20 mg/day) or placebo. Severity of illness was assessed biweekly by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Analysis of covariance with baseline Y-BOCS score included as a covariate was used to compare improvement in Y-BOCS scores in the 2 groups. Response was defined as a 25% or greater improvement in Y-BOCS score. Data were collected between April 2001 and May 2003. RESULTS: Outcome was assessed for all patients using the last observation carried forward. Subjects in the olanzapine group had a mean decrease of 4.2 (SD = 7.9) in Y-BOCS score compared with a mean increase in score of 0.54 (SD = 1.31) for subjects in the placebo group (F = 4.85, df = 2,23; p =.04). Six (46%) of 13 subjects in the olanzapine group showed a 25% or greater improvement in Y-BOCS score compared with none in the placebo group. The final mean dose of olanzapine was 11.2 (SD = 6.5) mg/day. Medication was well tolerated. Only 2 (15%) of 13 subjects who received olanzapine discontinued because of side effects: sedation (N = 1) or weight gain (N = 1). CONCLUSION: These results provide preliminary evidence that adding olanzapine to SRIs is potentially efficacious and well tolerated in the short-term treatment of patients with refractory OCD. Controlled studies with larger sample sizes are necessary to more definitively address this treatment strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, second-generation antipsychotic agents have shown benefit, either alone or as adjunctive therapy. Specifically, high-dose olanzapine [522], quetiapine [523], and risperidone [524] have all shown at least minimal clinical benefit relative to placebo treatment [525].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [522]
Citations
Cited by
Sorted by citations
Items 101–200 of 220
New Trends in the Treatment of Anxiety Disorders
Brawman‐Mintzer, O., & Yonkers, K. A. (2004) · CNS Spectrums · doi:10.1017/s1092852900002339 · Cited by 15
Pharmacotherapy for obsessive—compulsive disorder
Fineberg, N. A., & Brown, A. (2011) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.109.007237 · Cited by 15
Effects of quetiapine on cognitive functioning in obsessive???compulsive disorder
de Geus, F., Denys, D. A. J. P., & Westenberg, H. G. M. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32801182f7 · Cited by 15
“…et al., 2000; Koran et al., 2000; Francobandiera, 2001; Crocq et al., 2002; D’Amico et al., 2003; Marazziti et al., 2005) and two placebocontrolled (Bystritsky et al., 2004; Shapira et al., 2004) on olanzapine, and five open (Denys et al., 2002; Mohr et al., 2002; Sevincok and Topuz, 2003; Misri…”
BackgroundThe use of antipsychotics in obsessive compulsive disorder
Conti, D., Girone, N., Boscacci, M., Casati, L., Cassina, N., Cerolini, L., Giacovelli, L., Viganò, C. A., Conde, M. M., Cremaschi, L., et al. (2024) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2893 · Cited by 15
“Yet, the evidences are scarce: only two RCT confronted olanzapine with placebo (Bystritsky et al., 2004; Shapira et al., 2004) and one confronted it with risperidone (Maina, 2008).”
BackgroundKaradağ, F., Oğuzhanoğlu, N. K., Yüksel, D., Kıraç, S., Cura, Ç., Özdel, O. İ., & Ateşçi, F. Ç. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2012.07.005 · Cited by 13
“In such cases, the addition of a low dose atypical antipsychotic, such as risperidone or olanzapine, to ongoing SSRI treatment has been shown to be effective (McDougle et al., 2000; Bystritsky et al., 2004).”
BackgroundCitalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder
Fontenelle, L. F., Mendlowicz, M. V., Miguel, E. C., & Versiani, M. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029740 · Cited by 13
“2000), olanzapine (Bystritsky et al. 2004), and quetiapine (Denys et al.”
BackgroundHiguma, H., Kanehisa, M., Maruyama, Y., Ishitobi, Y., Tanaka, Y., Tsuru, J., Hanada, H., Kodama, K., Isogawa, K., & Akiyoshi, J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.551667 · Cited by 12
“…Scale (Endicott et al. 1976) were administered at the fi rst visit, following chronic SSRI compared with simply extending the monotherapy trial, while Bystritsky et al. (2004) reported that adding olanzapine to SSRIs is potentially effi cacious in the short-term treatment of patients with…”
ResultPittenger, C., Bloch, M. H., Wegner, R., Teitelbaum, C., Krystal, J. H., & Coric, V. (2006) · Primary psychiatry · Cited by 12
Cognitive behavioral therapy in pharmacoresistant obsessive–compulsive disorder
Praško, J. P., Vyskocilova, J., & Sipek, J. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s101721 · Cited by 11
Murphy, T. K., Frazier, S., & Kim, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-252-6_10 · Cited by 11
Issues in the Pharmacological Treatment of Anxiety Disorders
Starčević, V. (2005) · Australasian Psychiatry · doi:10.1080/j.1440-1665.2005.02225.x · Cited by 11
Bipolar disorder and anxiety disorders.
Látalová, K., Praško, J. P., Grambal, A., Havlikova, P., Jelenova, D., Mainerová, B., Kamarádová, D., Ocisková, M., Sedlackova, Z., & Sandoval, A. (2013) · PubMed · Cited by 11
Berlin, H. A., Hamilton, H., & Hollander, E. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20045 · Cited by 10
Biological treatments for obsessive-compulsive and related disorders
Borue, X., Sharma, M., & Hudak, R. (2015) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2015.03.003 · Cited by 11
Atypical antipsychotics for mood and anxiety disorders: Safe and effective adjuncts?
Blier, P. (2005) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0531 · Cited by 10
Abdel-Ahad, P., & Kazour, F. (2015) · Current Clinical Pharmacology · doi:10.2174/15748847113089990060 · Cited by 9
Are placebo-controlled trials still important for obsessive compulsive disorder?
Fineberg, N. A., Hawley, C. J., & Gale, T. M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.012 · Cited by 9
Evidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., Brown, A., & Pampaloni, I. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.009 · Cited by 9
“Bystritsky et al. (2004) conducted a 6 wk, double-blind, placebo-controlled study of adjunctive olanzapine in 26 OCD patients who had failed to respond to SRI monotherapy.”
BackgroundMethodInfluentialThe problem of delusional ugliness: Is it really body dysmorphic disorder?
Fontenelle, L. F., Mendlowicz, M. V., Kalaf, J., & Versiani, M. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500287420 · Cited by 10
“…does not respond to the latter class of drugs if BDD is said to belong to the OCD spectrum (Phillips et al. 1995) and OCD itself responds to augmentation with typical (McDougle et al. 1994) as well as atypical antipsychotics (McDougle et al. 2000; Bystritsky et al. 2004; Denys et al. 2004).”
BackgroundTakeda, T., Sumitani, S., Hamatani, S., Yokose, Y., Shikata, M., & Ohmori, T. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s127752 · Cited by 8
“augmentation strategy for SSRIs in SSRI-resistant OCD patients.(6,7) However, it is not clear how to predict response to pharmacotherapy in each OCD patient.”
BackgroundA Review of Antipsychotics in the Treatment of Obsessive Compulsive Disorder
Fineberg, N. A., Gale, T. M., & Sivakumaran, T. (2007) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.5.3.foc354 · Cited by 8
Franklin, M. E., & Simpson, H. B. (2005) · Journal of Cognitive Psychotherapy · doi:10.1891/088983905780907676 · Cited by 7
Tourette's disorder: Genetic update, neurological correlates, and evidence-based interventions.
Phelps, L. (2008) · School Psychology Quarterly · doi:10.1037/1045-3830.23.2.282 · Cited by 7
Polymorphic and Posttranscriptional Modifications of 5-HT Receptor Structure
Davies, M. A., Chang, C.-Y., & Roth, B. L. (2006) · The Receptors · doi:10.1007/978-1-59745-080-5_3 · Cited by 5
Pharmacological Treatment of Internet Addiction
Camardese, G., Leone, B., Walstra, C., Janiri, L., & Guglielmo, R. (2017) · Studies in neuroscience, psychology and behavioral economics · doi:10.1007/978-3-319-46276-9_14 · Cited by 5
Gautam, M. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001716 · Cited by 4
“Three RCTs were identified for olanzapine with negatively mixed results.(53,62,63) A trial by Bystritsky et al(63) showed that augmentation with olanzapine at a mean dose of 11 mg demonstrated significant reductions in Y-BOCS scores.”
ResultAn emerging role for escitalopram in the treatment of obsessive-compulsive disorder
Hedges, D. W., & Woon, F. L. M. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a921 · Cited by 4
“…a double-blind, placebo-controlled study of treatment-refractory subjects with OCD already taking fl uoxetine, paroxetine, sertraline, or clomipramine, Bystritsky et al (2004) reported that the addition of the second-generation antipsychotic olanzapine to an SSRI in a double-blind, randomized trial…”
Pharmacotherapy of Obsessive-Compulsive Disorder During Breastfeeding
Uğuz, F. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000500 · Cited by 4
“Despite the availability of double-blind controlled studies and meta-analyses about efficacy antidepressants and antipsychotics in general patients with OCD, there are no similar studies in postpartum women with OCD.”
BackgroundInfluentialMurphy, T. K., Stewart, S. E., & Obregon, D. F. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_10 · Cited by 6
Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy
Ameringen, M. V., Mancini, C., Patterson, B. A., & Truong, C. (2008) · Medical psychiatry · doi:10.3109/9780849382666.012 · Cited by 4
Arnold, P. D., & Kronenberg, S. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch60 · Cited by 4
Troubles bipolaires et symptômes dits névrotiques
Aouizerate, B. (2006) · L Encéphale · doi:10.1016/s0013-7006(06)76176-0 · Cited by 3
“Concernant les antipsychotiques, retenons l’étude rispéridone versus olanzapine dans l’état de stress posttraumatique et le trouble obsessionnel compulsif (2, 6, 21, 33).”
BackgroundMarouf, F., Giallourakis, C. C., Baer, L., Hanau, M. S., & Holbert, B. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1215968 · Cited by 3
O’Reilly, D. J., Goeree, R. A., Tarride, J., James, C., & Parfrey, P. S. (2009) · PubMed · Cited by 3
OBSESSIVE-COMPULSIVE DISORDERS
Dougherty, D. D., & Jenike, M. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50054-8 · Cited by 3
Intelligence quotient level and treatment of obsessive-compulsive disorders: Meta-analyses
Hu, L., Hao, Y., Liu, S., Kang, H., Li, Q., Zeng, Z., Abdelrahim, M. E. A., & Tan, Y. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109995 · Cited by 5
A review of the pharmacotherapy of obsessive-compulsive disorder and schizophrenia: The case of sam
Randhawa, R. S. (2005) · Cognitive and Behavioral Practice · doi:10.1016/s1077-7229(05)80067-7 · Cited by 3
Ducasse, D., & Fond, G. B. (2013) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2013.09.001 · Cited by 2
Current management of obsessive and phobic states
Goljevscek, S. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s17032 · Cited by 2
Látalová, K., Kamarádová, D., & Praško, J. P. (2010) · Cited by 2
Internet Gaming Disorder Treatment Options in the Hospital Setting
Park, J. H., Hyun, G. J., Son, J. H., & Lee, Y. S. (2015) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.2015.26.2.75 · Cited by 2
Treatment-Resistant Obsessive-Compulsive Disorder (OCD): Focus on Antipsychotic Augmentation to SRIs
Albert, U., Cori, D. D., Bogetto, F., & Maina, G. (2014) · ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) · Cited by 2
Özen, M. E., Kalenderoğlu, A., Çelik, M., Örüm, M. H., & Hocaoğlu, Ç. (2019) · Adıyaman Üniversitesi Sağlık Bilimleri Dergisi · doi:10.30569/adiyamansaglik.477617 · Cited by 2
Tretmanski pristupi ovisnosti o Internetu
Mandić, S., Hundrić, D. D., & Ricijaš, N. (2019) · Kriminologija & socijalna integracija : časopis za kriminologiju, penologiju i poremećaje u ponašanju · doi:10.31299/ksi.27.2.5 · Cited by 3
Approaches to Treatment Resistance
Pallanti, S., Grassi, G., & Cantisani, A. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch5 · Cited by 2
Pharmacotherapy of Obsessive‐Compulsive Disorder
Decloedt, E. H., & Stein, D. J. (2012) · Wiley eBooks · doi:10.1002/9781119941125.ch2 · Cited by 2
Zai, G. C., Zai, C. C. H., Burroughs, E., Arnold, P. D., Kennedy, J. L., & Richter, M. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111428 · Cited by 3
Shahtou, A., Omara, H. R., Qari, S. A., Alqahtani, R. S., Alnasyan, Z. S., Alotaibi, A. E., Ali, A. A., Alabdulrahim, J. M., Naser, S. A., Asad, N., et al. (2026) · Cureus · doi:10.7759/cureus.108358 · Cited by 1
“In addition, the vast majority of the included RCTs were limited to the acute phase (4 to 12 weeks) [46,55,69].”
Augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder
Goddard, A. W., & Shin, Y. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511973796.005 · Cited by 1
Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen
Volz, H. (2009) · Springer eBooks · doi:10.1007/978-3-211-79826-3_8 · Cited by 1
Issler, C. K., Kapczinski, F. P., & Lafer, B. (2004) · Cited by 1
Session 4: Exposure and Ritual Prevention—Introducing Imaginal Exposure
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0007 · Cited by 1
Sayyah, M., & Rahim, F. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i1.14528 · Cited by 2
“2004, USA [120] A randomized, double-blind, placebo-controlled trial Y-BOCS, CGI RIS PBO 12 week 16 adult treatment-resistant OCD patients Hollander et al.”
MethodSimpson, H. B., & Harrison-Read, P. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.037 · Cited by 1
Voderholzer, U., & Hohagen, F. (2006) · Elsevier eBooks · doi:10.1016/b978-343724130-7.50013-4 · Cited by 1
Biological Models and Treatments for OCD in Adults
Stewart, S. E., & Loh, A. S. (2017) · Wiley eBooks · doi:10.1002/9781118890233.ch14 · Cited by 1
(2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.002.0005
PANDAS-Related Obsessive-Compulsive Disorder: A Single Case of "Failure" Reconsidered
Richards, J. G. (2009) · CommonKnowledge Research Repository (Pacific University Oregon)
Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder
Rapoport, J. L., & Inoff‐Germain, G. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn028
Harrington, P. M. (2006) · Texas ScholarWorks (Texas Digital Library)
Francis, B., Jambunathan, S. T., & Pillai, S. K. (2014) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2014.44035
Il trattamento del disturbo ossessivo-compulsivo resistente
Aguglia, A., Albert, U., Cori, D. D., Maina, G., & Bogetto, F. (2011) · Quaderni Italiani di Psichiatria · doi:10.1016/j.quip.2010.12.003
Revisión de los antipsicóticos atípicos en la ansiedad
Vulink, N. C. C., Figee, M., & Denys, D. A. J. P. (2012) · Psiquiatría Biológica · doi:10.1016/j.psiq.2012.10.002
Ducasse, D. (2013) · Journal of Depression & Anxiety · doi:10.4172/2167-1044.s10-001
Ferrão, Y. A., Diniz, J. B., Lopes, A. C., Shavitt, R. G., Greenberg, B. D., & Miguel, E. C. (2007)
[Therapeutic strategies for obsessive-compulsive disorder refractory to treatment].
Mussa, A. (2008) · PubMed
The Use of Antipsychotics in the Treatment of Obsessive-Compulsive Disorder
Walsh, K. H., Scott, E. L., & McDougle, C. J. (2008) · Psychopharm Review · doi:10.1097/01.idt.0000314887.61319.fa
“A unique crossover study compared 2-week adjunct treatment with HAL (2 mg daily), RIS (1 mg daily), or placebo, with a 1-week placebo washout between treatment arms.(30) HAL was poorly tolerated, extrapyramidal prophylaxis was not routinely supplied, and three of 16 patients developed dystonia necessitating early term…”
BackgroundMethodInfluentialSession 3: Exposure and Ritual Prevention—Introducing In Vivo Exposure
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0006
Intermediate Sessions: Continuing Exposure and Ritual Prevention
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0008
Problems Commonly Encountered during Exposure and Ritual Prevention (EX/RP)
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0010
Obesity and Impulsive and Compulsive Disorders
Soorya, L. V., Baker, B. R., Sharma, L., & Hollander, E. (2006) · CRC Press eBooks · doi:10.3109/9780849374517.007
Session 2: Treatment Planning Part II
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0005
Session 1: Treatment Planning Part I
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0004
Treatment Components of Exposure and Ritual Prevention
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0003
Voderholzer, U., & Hohagen, F. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50016-2
Ferrão, Y. A., Diniz, J. B., Lopes, A. C., Shavitt, R. G., Greenberg, B. M., & Miguel, E. C. (2007) · DOAJ (DOAJ: Directory of Open Access Journals)
Managing a Child With OCD Who Is Treatment Refractory
Bloch, M. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811427-8.00017-4
Pae, C., & Patkar, A. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50056-1
(2010) · Wiley eBooks · doi:10.1002/9781118269954.refs
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0009
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0002
Kombinationen mit Psychopharmaka in der Behandlung von Angst- und Zwangsstörungen
Volz, H. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_8
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as06
(2007) · Elsevier eBooks · doi:10.1016/b978-2-294-70195-5.50010-4
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as06
Introductory Information for Therapists
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.003.0001
Meuffels, Y., & Bervoets, C. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.071
Ballon, J. S., Nunes, J. C., & Salaheldin, K. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as27
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1
Case 24-2024: A 30-Year-Old Woman with Postpartum Anxiety and Intrusive Thoughts
Meltzer-Brody, S. E., Cohen, L. S., & Miller, E. S. (2024) · New England Journal of Medicine · doi:10.1056/nejmcpc2312735
Voderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_6
Imaginal Exposure Homework Recording Form
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.005.0015
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.005.0004
Foa, E. B., Yadin, E., & Lichner, T. K. (2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.005.0010
(2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.005.0020
(2012) · Oxford University Press eBooks · doi:10.1093/med:psych/9780195335286.002.0004
Metadata
- Authors
- Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-04-15
- Volume
- 65
- Issue
- 4
- Pages
- 565-568
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1988849721
- Cited by
- 220
- References
- 0
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 6 · 2015: 11 · 2014: 11 · 2013: 8 · 2012: 41
- FWCI
- 23.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, olanzapine, serotonin reuptake inhibitors, drug augmentation, atypical antipsychotics, Yale-Brown Obsessive Compulsive Scale, drug tolerability
- MeSH terms
- Olanzapine, Adult, Benzodiazepines, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Antipsychotic Agents, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
